<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083911</url>
  </required_header>
  <id_info>
    <org_study_id>DAC-HAAG-02</org_study_id>
    <nct_id>NCT04083911</nct_id>
  </id_info>
  <brief_title>Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60</brief_title>
  <official_title>A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Elderly Newly Diagnosed Acute Myeloid Leukemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changzhou No.2 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Lianyungang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jingjiang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhangjiagang First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Huai'an</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Kunshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG
      regimen in the induction treatment of newly diagnosed AML patients older than 60 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, open Label, single arm, multi-center study in elderly newly diagnosed AML
      patients. The patients will receive DAC combined with HAAG in the induction treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Day 28-35 of induction course</time_frame>
    <description>ORR includes complete response (CR), CRi and PR. CR was defined as &lt; 5% bone marrow blasts in an aspirate with spicules, no blasts with Auer rods or persistence of extramedullary disease, and independent of transfusions; CRi: was defined as&lt;5% bone marrow blasts, either ANC&lt;1×10^9/L or platelets&lt;100×10^9/L, transfusion independence but with persistence of cytopenia; PR was defined as decrease of at least 50% in the percentage of blasts to 5-25% in the bone marrow aspirate and the normalization of blood counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival (LFS)</measure>
    <time_frame>3 years</time_frame>
    <description>time from randomization to the first relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>3 years</time_frame>
    <description>time from achievement of a remission to the first relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>adverse events are evaluated with CTCAE V5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Induction Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Decitabine combined with HAAG Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will determine the safety and efficacy of decitabine combined with HAAG regimen in elderly newly diagnosed AML patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF</intervention_name>
    <description>Decitabine:20mg/m2/d, d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~9,intravenous infusion; Aclarubicin:10mg/d, d3~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;
Granulocyte colony-stimulating factor:
50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;</description>
    <arm_group_label>Decitabine combined with HAAG Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed AML according to the WHO (2016) classification of acute myeloid
             leukemia.

          2. 60-79 years old.

          3. ECOG score: 0-3.

          4. No history of previous chemotherapy or target therapy.

          5. Provide informed consent.

        Exclusion Criteria:

          1. Patients have acute promylocytic leukemia or chronic myeloid leukemia in blast crisis.

          2. Patients with another malignant disease.

          3. Patients with uncontrolled active infection.

          4. Patients with left ventricular ejection fraction &lt; 0.5 by echocardiography or grade
             III/IV cardiovascular dysfunction according to the New York Heart Association
             Classification.

          5. Patients with aspartate aminotransferase or glutamic-pyruvic transaminase &gt; 3x upper
             limit of normal or bilirubin &gt; 2.0 mg/dL.

          6. Patients with creatinine clearance rate &lt; 50ml/min.

          7. Patients with active hepatitis B or hepatitis C infection.

          8. Patients with HIV infection.

          9. Patients with other commodities that the investigators considered not suitable for the
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaowen Tang, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowen Tang, Ph.D.</last_name>
    <phone>(0086)51267780086</phone>
    <email>xwtang1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Depei Wu, Ph.D.</last_name>
    <phone>(0086)51267780086</phone>
    <email>wudepei@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowen Tang, Ph.D.</last_name>
      <phone>(0086)51267780086</phone>
      <email>xwtang1020@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 8, 2019</last_update_submitted>
  <last_update_submitted_qc>September 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Decitabine, HAAG, AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Homoharringtonine</mesh_term>
    <mesh_term>Aclarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

